Evidence map›Paper›PMID 40561525›Full record

ArticleBlood advances2025

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.

Jessica S Little, Angelica Medina Pena, E Bridget Kim, Andrew J Yee, Omar Nadeem, Shonali Midha, Adam S Sperling, Nikhil C Munshi, Noopur Raje, Matthew J Frigault and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jessica S LittleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-8093-5647
Angelica Medina PenaDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
E Bridget KimDepartment of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Andrew J YeeDepartment of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-3623-7491
Omar NadeemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Shonali MidhaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Adam S SperlingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-9369-4413
Nikhil C MunshiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Noopur RajeDepartment of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Matthew J FrigaultDepartment of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Diana D CirsteaDepartment of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-5719-581X
Sarah P HammondDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-4271-7443

Funding

Defining mechanisms of thalidomide analog resistanceK08CA252174 · NCI · DANA-FARBER CANCER INST · PI SPERLING, ADAM · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA252174
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40561525
PMCPMC12361759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.